- Home
- XERS vs RERE Comparison
XERS vs RERE Comparison
Compare XERS & RERE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | RERE |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.3M | 859.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XERS | RERE |
|---|---|---|
| Price | $5.48 | $4.80 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $10.83 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 1.3M |
| Earning Date | 03-02-2026 | 03-11-2026 |
| Dividend Yield | N/A | ★ 1.95% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $28.65 | $26.81 |
| Revenue Next Year | $18.33 | $22.92 |
| P/E Ratio | ★ N/A | $34.57 |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $3.81 | $2.00 |
| 52 Week High | $10.08 | $6.47 |
Technical Indicators
Market Signals| Indicator | XERS | RERE |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 36.18 |
| Support Level | $4.30 | $3.87 |
| Resistance Level | $5.49 | $4.89 |
| Average True Range (ATR) | 0.24 | 0.29 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 12.43 | 0.00 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.